Assetmark, Inc Theravance Biopharma, Inc. Transaction History
Assetmark, Inc
- $41.6 Billion
- Q2 2025
A detailed history of Assetmark, Inc transactions in Theravance Biopharma, Inc. stock. As of the latest transaction made, Assetmark, Inc holds 51 shares of TBPH stock, worth $752. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51Holding current value
$752% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TBPH
# of Institutions
140Shares Held
48.7MCall Options Held
0Put Options Held
11.6K-
Madison Avenue Partners, LP New York, NY9.51MShares$140 Million11.23% of portfolio
-
Weiss Asset Management LP Boston, MA7.46MShares$110 Million1.24% of portfolio
-
Newtyn Management, LLC New York, NY4.95MShares$73 Million10.56% of portfolio
-
Black Rock Inc. New York, NY3.78MShares$55.8 Million0.0% of portfolio
-
Irenic Capital Management LP New York, NY2.76MShares$40.7 Million4.49% of portfolio
About Theravance Biopharma, Inc.
- Ticker TBPH
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 66,782,400
- Market Cap $985M
- Description
- Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...